Shares of BioNTech rose after the company said it plans to deliver over 2.2 billion vaccination doses this year.
Good news for BioNTech shareholders.
As of 1:00 p.m. today, the company's stock rose over 14 percent today after BioNTech said they signed agreements for about 2.2 billion doses this year.
In a press release, the company stated that along with partner Pfizer, they've crossed the one billion mark for COVID-19 vaccinations after only six months.
BioNTech also stated that over a billion doses have been ordered for 2022 and beyond.
Ugur Sahin, BioNTech Cofounder, also notes that they're expanding their vaccine supply to over 100 countries.
"To address the ongoing pandemic, we are expanding the supply of our COVID-19 vaccine to more than 100 countries and regions worldwide, including enhancing access to low- and middle-income countries. At the same time, we further developed our oncology pipeline, including the recent initiation of randomized Phase 2 trials for two FixVac programs."
The statement also says the companies are conducting multiple clinical trials on the effects of the vaccine on children between 6 months to 11 years old.
Welland Building Owner Fined
Lincoln EarlyON Child Centre Opens
Too Many Niagara Politicians: Chair
City Maintaining Doctor Recruitment in Budget
Marineland to Make Next Move: Minister
Opinions Wanted on Port Colborne Future
Welcoming Streets Initiative Approved
NRP Officer Cleared of Wrongdoing